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Abstract 
The Polymers are tools used in novel drug delivery system to modify the drug release of 
pharmaceutical dosage form. Ondansetron HCl is a weakly basic drug belongs to BCS class-
II; it is showing distinct pH dependent solubility. The major intention of the current study was 
to develop a pH independent controlled released system for pH dependent poorly soluble 
Ondansetron HCl. The effect of combination of polymers on parameters like release pattern, 
release mechanism of the drug were studied. A 3
2 
full factorial design was used to study the 
effect of Kollidon SR on Ondansetron HCl Drug Release from Hydroxypropyl Methyl 
Cellulose Matrix Tablets. The release rate from formulated matrix tablets was studied at both 
SGF (pH 1.2) and SIF (pH 6.8).  Drug release from  Kollidon SR and Methocel (1:1) based  
matrix system based tablets was found to  pH independent controlled  drug release up to 24h 
with  >90% drug release. Kollidon SR has a distinctive character of maintaining tablets 
geometric shape until the end of dissolution test, this is mainly due to the water insoluble 
content, polyvinyl acetate, forming 80% (w/w) of Kollidon SR, while the remaining content 
20% (w/w) is the water soluble, polyvinylpyrrolidone, responsible for pore formation causing 
a diffusion controlled release The similarities in Release profiles were evaluated by applying 
the model independent (f2) similarity factor. The Optimized formulation characterized by 
DSE, X-RD and FT-IR studies was found not having any interaction with polymer and drug. 
The Optimized Formulation followed zero order with non-Fickian diffusion method. In 
conclusion, Kollidon SR and Methocel k100 were found to be novel potential candidates for 
the development of pH independent controlled delivery system of Ondansetron HCl. 
 
Keywords: Ondansetron hydrochloric acid; pH independent controlled drug delivery system,     
Kollidon® SR, METHOCEL K100M 
 
INTRODUCTION 
The oral drug delivery is by far the most 
preferable route of drug delivery system, 
due to ease of administration, patient 
compliance and flexibility in formulation. 
Most of the active pharmaceutical 
ingredients are weak acids And weak 
bases these salts showed variable drug 
release pattern in different areas of GIT, 
weakly basic drugs are highly soluble in 
acidic pH and the solubility was reduced to 
increase the pH shift to the intestinal pH 
6.8 Phosphate medium, due to pH 
dependent solubility, such a type of drugs 
is not easy to formulate a controlled 
release dosage form to the formulator [1]. 
Ondansetron hydrochloride is a serotonin 
sub type-3 (5-hydroxytryptamine-3) 
receptor antagonist [2]. It is a widely used 
drug for the treatment of several 
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therapeutic purposes like antiemetic 
especially it is used in the prevention of 
post operative nausea and vomiting and 
chemotherapy or radiation induced nausea 
and vomiting.  The solubility it exhibit 
high in stomach at low pH (pH 1.2) at 
37

C (23mg/ml) and at higher pH (6.8 pH 
phosphate buffer) it exhibits poor 
solubility (0.036 mg/ml) and precipitation 
of drug was found. It indicates incomplete 
results, irregular drug absorption and 
fluctuations in plasma concentrations.  It 
causes either it will not reach therapeutic 
levels or it may leads to toxic levels. pH 
independent controlled released matrix 
tablets is a special type of controlled 
release drug delivery system. The 
convenience of obtainable literature 
indicate that a number of methods have 
been attempt to developed pH-independent 
controlled drug release [3]. away of that, 
one is gastro retentive drug delivery 
system in which the drug will float 
constantly for long period of time which is 
a question mark and also in-vitro/in-vivo 
correlation is very poor [4]. And another 
technique was developed pH adjuster such 
as organic acids this technique was 
somewhat better but the formulator was 
observed some manufacturing defects and 
prolonged drug release is very difficult [5-
6].  
 
Hydrophilic polymers were chosen 
because of its controlled release a well as 
good pH independent release polymer [9]. 
The pH independent swelling of HPMC is 
attributable to the constant drug release in 
entire pH of GIT [10]. Kollidon SR it is a 
convincing polymer is expected to be 
easily applicable for pH independent 
controlled released matrix tablets by direct 
compressible method [11].The present 
investigation is aimed to develop a pH-
independent control drug release dosage 
form of by using Kollidon® SR for 
achieving the constant drug release 
irrespective of any pH and it will give 
assurance and useful information for novel 
approach to develop controlled release 
products commercially [12]. The Kollidon 
SR is a potentially useful novel excipient 
for the production of pH-independent 
extended release matrix tablets. It will be 
useful for all the pH-dependent soluble 
drugs. The objective of the present 
investigation was to study the effect of 
various polymers and their Concentration 
on the drug release characteristics, pH 
independent drug release, and other 
physicochemical properties of the tablet 
dosage form. Ondansetron was used as the 
model drug to study the release 
characteristics of the formulated tablet 
dosage form as it is pH dependent soluble 
drug. The recommended oral dose regimen 
of Ondansetron hydrochloride is 8 mg, 
three times a day. The dose of 
Ondansetron hydrochloride should be 
flexible in the range of 8-32 mg a day. The 
selection of dose regimen should be 
determined by the severity of the 
Emetogenic. The present study was 
undertaken to once daily pH independent 
controlled released matrix tablets and to 
check the Influence of variation in the 
concentration of different polymers on the 
release rate of the drug and the 
physicochemical properties of the dosage 
form. 
 
MATERIALS AND METHODS 
Ondansetron HCl was obtained from 
Pranami Drugs Pvt. Ltd., Gujarath, 
Hydroxy Propyl Methyl Cellulose 
(Methocel K100M), Kollidon SR were 
supplied by Yarrow chemicals ,  Mumbai, 
India, AVICEL PH 101 was procured from 
Qualigens Fine Chemicals Lactose and 
Magnesium Stearate obtained from Aman 
chemicals(Vijayawada, AP), respectively 
 
Preparation of Ondansetron HCl 
Matrix Tablets 
All the tablet formulations with different 
drug and polymer ratios were prepared by 
direct compression method. Kollidon® SR 
and Methocel k100M was chosen, for its 
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pH independent controlled released 
property. controlled release matrix tablets 
were prepared by direct compression 
method as per the formula given in the 
Table 1 .Initially the drug was passed 
through sieve no #30,  different polymer 
concentrations passed sieve no #40 ,Avicel 
PH 101,lactose and magnesium stearate , 
talk. These powders were mixed until a 
homogenous mixture was obtained. 
Ondansetron and all other ingredients were 
exactly weighed and sifted through sieve 
no# 40. The materials were mixed and 
blended in a mortar. Finally the blend was 
compressed using 8 mm diameter, flat 
faced die and punches (Cadmach tablet 
press, India). Hardness for all the 
formulations was adjusted to 5-6 kg/cm
2 
(Monsanto hardness tester-Macro 
Scientific Works, Delhi, India). With 
average weight of the Tablet is 
300mg.physicochemical properties for 
various parameters were evaluated for 
prepared tablets. (table.1) 
Selection of experimental design 
A 3
2 
factorial design was selected for the 
study. Two main factors i.e. combination 
of the polymer and ratio were evaluated at 
different concentrations. Three levels of 
the factor X1 (concentration of HPMC 
K100M) and   X2 (Kollidon SR) selected 
to find out its effect on drug release. While 
ratios of polymers at three levels were 
selected to identify separate as well as 
combined effects of both controlled 
released polymers (HPMCK100M) . 
Percentage of drug release after 2 h 
(>20%) and percentage of drug release 
after 20 h (<90%) were selected as 
dependent variables. In this design, two 
factors were studied at three levels and 
experimental trials were performed at all 
nine possible combinations.Composition 
of the 3
2
 full factorial design investigated 
is shown in (Table 2). 
 
Table 1: Priliminary Formulations of Ondansetron without pH modulating agents. 
INGREDIENTS P1 P2 P3 P4 P5 P6 P7 P8 
Ondansetron HCl 25 25 25 25 25 25 25 25 
Methocel K100M 25 50 75 100 - - - - 
Kollidon Sr - - - - 25 50 75 100 
PVP 3 3 3 3 3 3 3 3 
Avicel PH102 236 211 186 161 236 211 186 161 
Megnisium Stearate 6 6 6 6 6 6 6 6 
Talc 6 6 6 6 6 6 6 6 
Total (Mg) 300 300 300 300 300 300 300 300 
 
Table 2:  3
2
 full factorial design. 
Formulation code 
Coded values 
X1 X2 
F1 -1 -1 
F2 -1 0 
F3 -1 1 
F4 0 -1 
F5 0 0 
F6 0 1 
F7 1 -1 
F8 1 0 
F9 1 1 
Translations of coded values to actual values 
Coded values -1 0 1 
Methocel k100m 25 50 75 
Kollidon SR 25 50 75 
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Angle of Repose 
Angle of repose was determined for the 
powder blend as in indicator for 
favorability characteristic. Based on flow 
of the powder   the method was selected 
for tablet preparation. This was determined 
by a simple fixed funnel method the blend 
was poured through a dry funnel that can 
be raised vertically until a maximum cone 
height (h) was obtained. Radius of the 
heap(r) was measured and angle of repose 
was calculated by using the formula [13]. 
 
Hardness Test 
The hardness of matrix tablets was 
determined using Pfizer hardness tester. 
From each formulation batch three matrix-
tablets were randomly taken and the values 
were calculated. 
 
Friability Test 
The test was performed by initially 
weighing 5-tablets and then transferring 
into VEEGO Friabilator. The friabilator 
was operated at 25 rpm for 100 revolutions 
and the matrix-tablets weighed again. 
Friability was computed as percent loss in 
weight. 
 
Weight Variation Test 
From each formulation batch ten matrix-
tablets were randomly taken and weighed 
individually to determine variation. 
 
Uniformity of Thickness 
From each formulation batch, six matrix-
tablets were randomly taken and measured 
for thickness using a micrometer screw 
gauge. 
 
Drug Content Uniformity 
For estimation of drug content first five 
tablets were taken and then crushed into 
fine powder in the mortar. Then this fine 
powder equivalent to 25 mg of 
Ondansetron HCl was extracted in pH 
6.8.phosphate buffer. This sample was 
filtered through a Millipore filter of 0.45 
μm pore size. After suitable dilutions drug 
content was Spectrophotometry 
determined at a wavelength of 249 nm. 
[15]. 
 
Dissolution Studies 
The in-vitro drug release study was carried 
out by using USP Type–II, rotating paddle 
apparatus (VEEGO Instruments 
Corporation, Mumbai, India). The 
operating speed was at 50 rpm. SGF 
(pH1.2, 900 ml) was used as dissolution 
medium. The temperature was maintained 
at 37±0.5

C. Simultaneously we studied 
both pH 1.2 and 6.8 continuously for 
complete drug release study.  Samples 
were withdrawn at pre-determined time 
intervals, filtered and analyzed by using 
UV-Visible Spectrophotometer (ELICO 
SL-210) at 249 nm [12].  
 
Similarity factor analysis 
The dissolution profiles of the formulated 
Dipyridamol tablets were compared with 
both medium pH 1.2 and pH 6.8 phosphate 
buffer and evaluate pH-independent 
release pattern of dipyridomol from the 
optimized tablets in the release media of 
pH 1.2 and pH 6.8.Similarity (f2),  factors 
are using a similarity factor described in 
the following equation:   
𝑓2 = 50 × log {[1+ (1/n) Rj−Tj 
nj=1²]¯°˙⁵×100}   
 The Food and Drug Administration 
(FDA) and the European Agency for the 
Evaluation of Medicinal Products (EMEA) 
suggested that two dissolution profiles can 
be declared similar if f2 is between 50 and 
100 [8]. 
 
In- Vitro Drug Release (Mechanism): 
To know the mechanism of drug release 
from all these formulations, the data to be 
fixed to zero order (cumulative amount of 
drug released vs. time), first-order (log 
cumulative percentage of drug remaining 
vs. time), Higuchi’s (cumulative 
percentage of drug released vs square root 
of time), and Korsmeyer’s (log cumulative 
percentage of drug released vs. log time) 
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plotted and regression values were 
calculated [11]. 
 
Scanning Electron Microscopy Studies 
The Scanning electron microscopy studies 
were used to examine the solid state 
physical structure of the prepared 
precipitated form of the powder and pure 
ondansetron HCl. S.E.M. photographs of 
Ondansetron HCl, its physical mixture   
with different pH medium  were obtained 
using  a scanning electron microscope ( 
JEOL JSM 5600) with accelerating voltage 
from 0.5 to 30 KV.  
 
RESULTS AND DISCUSSION 
pH-Dependent solubility Of Weakly 
Basic Drug 
Solubility of ondansetron HCl was carried 
out in both mediums 0.1N HCl and 6.8 
phosphate buffer .the solubility of 
ondansetron in 0.1N HCl was found to be 
23.3 mg/ml. The solubility of Ondansetron 
HCl in pH 6.8 phosphate buffer was 
0.036mg/ml and the drug was immediately 
precipitated it formed large crystal shown in 
(Fig: 1). The solubility studies was revealed 
Ondansetron HCl is a completely pH 
dependent soluble drug. Hence in this 
investigation an attempt was made to develop 
a suitable pH independent controlled released 
matrix tablets of Ondansetron HCl. 
 
 
Figure 1: Laboratory Comparison of solubility (Ondansetron HCl) both acidic and basic 
medium. 
 
FT-IR Studies 
The FT-IR of Ondansetron HCl and 
polymer mixtures and optimized matrix 
tablets dosage form studied   by kbr 
pellet technique. The Ondansetron HCl 
exhibited characteristic peaks at 3,394 
and 1,633 cm, attributed to O-H 
stretching and C=O stretching 
vibrations. The physical sprectrum not 
showed significant shift in peaks of 
Ondansetron HCl  and somewhat 
changed some intensity peaks were 
found. And as well as optimized 
formulation of Kollidon SR with 
Methocel K100M  formulation were 
studied the band at 3,499 cm for O-H 
stretching and 1,699 cm for C=O 
Stretching were found. The results of IR 
spectroscopy reveal that there was no 
chemical interaction between 
Ondansetron and Kollidon SR with 
Methocel K100M combination of 
polymers.IR sprectra shown in (Fig no: 
2, 3). 
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Table 3: FTIR Spectral studies. 
Functional Groups Ondansetron HCl 
N- CH3  streching 3200 – 3180 
C=O acid Stretching 1635 – 1612 
C-H alkane stretching 2720 – 2662 
Aromatic stretching 750 – 772 
 
Figure 2:  IR Spectra of Ondansetron. 
 
 
             Figure 3: IR Spectra of Ondansetron HCl with HPMC K100+KOLLIDONE SR. 
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XRD Analysis 
XRD (X-Ray diffraction)  the freshly 
prepared powdered samples under 
controlled temperature and humidity 
conditions  were record at room 
temperature on X-Ray diffract meter with 
Cu Ka radiation (1.54 Å), at 40 kV, 30 
mA, passing through a nickel filter with a 
divergence slit (0.5°), anti-scattering slit 
(0.5°), and receiving slit (1 mm). The 
presence of many diverse peaks in the X-
ray diffraction pattern indicate that 
Ondensetron HCl API crystalline material 
with characteristic diffraction peaks 
appearing at a diffraction angle of 2θ at 
10.2, 19.2, 22.5, 29.11 & 35.6. The 
Optimized formulation containing 
Methocel k100M with koliidon SR 
exhibits a distinct pattern with 
diffraction peaks at diffraction angle of 
2θ at 7.82, 15.99 and 22.5. The 
diffraction pattern of placebo was found 
to differ in comparison with drug. Some 
peaks were disappeared, some peaks 
were appeared & some peaks heights 
were decreased. taken as a whole 
diffraction pattern revealed that there is 
no change in polymorphic properties of 
the drug and the drug is well distributed 
throughout the preparation of optimized 
formulation(F9) XRD results was shown 
in (Fig 4). 
  
 
                                  a)                                                                             b) 
Figure 4: (a) X-ray diffraction spectra of pure Ondansetron HCl (b) X-ray diffraction 
spectra of precipitated  powder Ondansetron HCl  in 6.8 Phosphate buffer. 
 
DSC Study 
DSC study was performing on the pure 
ondansetron HCl, and optimisized 
formulation with Methocel k100 and 
Kollidon SR used in the study. The 
drug: polymer complex to access 
whether there is any interaction between 
drug and polymer. The thermo gram of 
pure Ondansetron gave a melting 
endotherm at 203.25ºC. The thermo 
gram of optimized formulation gave the 
same melting endoderm 213 25ºC. So 
from the DSC curve it has been 
confirmed that there is no change in 
endothermic peak of the drug.  And 
hence the drug and polymers are well 
compatible with each other. [16]. DSC 
of spectrum was shown in (Fig 5). 
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                                  a)                                                                             b) 
Figure 5: (A) DSC thermo gram of pure ondansetron HCl (B). DSC thermo gram of 
precipitated powder ondansetron HCl in 6.8 Phosphate buffer 
 
Pre-compression evaluation for 
formulated of the Powder Mixture: 
Prior to compression,  all the formulations 
were evaluated for their flow property. 
From the values of Angle of repose, it is 
clear that blends having Kollidon SR 
formulation is showed better flow 
properties than Methocel K100M. The 
formulation containing (F1-F4) property 
was falling in the passable range 
(31.32±0.12) and Kollidon SR (F6-F9), 
flow property was falling in the excellent, 
in which values of angle of repose were 
found to be and 18.12±0.32 respectively, 
While formulation with Kollidon® SR 
with Methocel k100 (F9) had good flow 
property, The values of angle of repose 
were 24.23±0.32and 23.45_± 0.19 
respectively. The Bulk densities of the 
powder blends of all the formulations 
ranged from 0.331 to 0.521 g/cc and 
tapped densities of the powder blends of 
all the formulations ranged from 0.444 to 
0.842 g/cc. The Hausners ratio values 
ranged from 1.34 to 1.66. Evaluated values 
were less than 1.25 indicating good flow. 
It means that the powder flow properties 
were within the pharmacopoeias limits. 
The Carr’s index values ranged from 18 to 
35%. High compressibility is required for 
Kollidon SR when compared to Methocel 
k100. The results obtained indicates that 
the powder flow properties were within the 
pharmacopoeias limits, the Kollidon SR 
polymer was found excellent flow 
property.(Table 4). 
  
Table 4: Pre-compression Parameters of the Powder Mixture. 
Formulation 
code 
Bulk density 
(g/ml) 
Tapped density 
(g/ml) 
Compressibility 
index (%) 
Hausner’s 
ratio 
Angle of 
repose 
F1 0.337±0.031 0.444±0.001 25.45 1.34 31.32±0.12 
F2 0.347±0.011 0.424±0.006 18.16 1.22 25.21±0.32 
F3 0.346±0.021 0.458±0.009 24.45 1.32 29.45±0.24 
F4 0.356±0.021 0.468±0.012 23.93 1.31 30.23±0.17 
F5 0.501±0.009 0.833±0.0023 39.85 1.66 19.32±0.32 
F6 0.511±0.008 0.823±0.006 37.91 1.61 18.12±0.32 
F7 0.521±0.011 0.842±0.007 38.12 1.61 20.12±0.32 
F8 0.515±0.007 0.822±0.008 37.34 1.59 20.54±0.12 
F9 0.508±0.006 0.811±0.009 37.36 1.59 24.23±0.32 
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Table 5: Post-compression Parameters of the controlled released matrix tablets. 
Tablets Average weight,(mg) Thickness,(mm) Hardness Friability Drug content% 
F1 301±2 4.85 (0.008) 6.23  ±0.29 1.01 (0.51) 98.56  (2.12) 
F2 298±1 4.87 (0.006) 6.42 ±0.34 0.56 (0.11) 101.12  ( 1.23) 
F3 301±3 4.89 (0.005) 5.98 ±0.29 0.67 (0.21) 102.12  (3.12) 
F4 300±2 4.86 (0.009) 5.91 ±0.44 0.54 (0.52) 100.10  (4.2) 
F5 299±2 4.85 (0.004) 6.72 ±0.54 0.76 (0.20) 98.12   (5.2) 
F6 304±1 4.84 (0.009) 6.65 ±0.34 0.85 (0.08) 101.12  (4.3) 
F7 302±3 4.86 (0.008) 6.98 ±0.34 0.87 (0.22) 103.23  (3.8) 
F8 303±2 4.87 (0.005) 6.54 ±0.64 0.96 (0.07) 101.29  (2.3) 
F9 299±1 4.83 (0.005) 6.75 ±0.34 0.45 (0.31) 97.23   (5.2) 
F10 301±2 4.87 (0.007) 6.43 ±0.24 0.48 (0.41) 100.12  (4.5) 
 
Post-compression evaluation for 
formulated matrix tablets: 
The weight of the tablet varied between 
295 mg to 300 mg for different 
formulations with low standard deviation 
values, indicating uniformity of weight. 
The variation in weight was within the 
range of ±5% complying with 
pharmacopoeia specifications. The 
hardness for different formulations was 
found to be between 5 to 6.5 kg/cm
2
 
indicating satisfactory mechanical 
strength. The friability was below 1% for 
all the formulations, which is an indication 
of good mechanical resistance of the 
tablet. All the tablet formulations showed 
acceptable pharmacopoeias limits, the 
result are presented in (Table 5).                                          
 
In-Vitro Drug Release Studies: 
In-vitro dissolution studies for all 
formulations were performed using the 
two–step dissolution method, in vitro 
dissolution studies were performed in both 
pH 1.2 and ph 6.8 buffers individually and 
by changing the pH, which better 
corresponds to real conditions in the gastro 
intestinal tract 2h in pH 1.2 and following 
in pH6.8 mediums, to see the effect of 
change in the pH of the dissolution 
medium on drug release. Results obtained 
in the in vitro drug release study of 
different formulations. A remarkable 
difference in the drug release from one 
polymer to another polymer formulations. 
From that Methocel k100M and 
Kollidon® SR at different proportions of 
drug and polymer ratios.  The drug release 
was observed in pH 1.2 SGF and pH 6.8 
phosphate buffer. The drug release from 
the matrix tablet   in pH 1.2 was relatively 
faster from all the formulations but it was 
variable from polymer to polymer drug 
release in pH 6.8 phosphate buffer. when 
formulation containing with optimized 
concentration of Methocel K100M ( 
P4,1:4 ratio), approximately 22.24% in pH 
1.2 after 2h and 64% of drug release  in 
6.8 phosphate buffer after 24h 
respectively, It  was Showed incompletely 
drug release and drug was not released 
complete from matrix device pH 
dependent  drug release was found  the 
drug released . However, in case of  
Kollidon SR( P8,1:4 ).the drug release was 
found  approximately 57.24% in pH 1.2 
after 2h and 96% of drug release  in 6.8 
phosphate buffer after 6h respectively, 
polymeric matrices showed quite a faster 
release in both pH 1.2 after 2h and 6.8 
phosphate buffer  with Kollidon SR ,the 
main reason for this Kollidon SR 
containing the water insoluble part; 
polyvinyl acetate, forming 80% (w/w)  that 
maintains tablet shape and controlled the 
drug release, while the remaining part 20% 
(w/w) is the water soluble, 
Polyvinylpyrrolidone that dissolve in 
water exit open pores inside which water 
access from matrix device to dissolve the 
drug causing a diffusion controlled release 
mechanism  [16]. It was found that 
Kollidon SR is enhancing the drug release 
in pH 6.8 phosphate buffer but drug 
release is not controlling in pH 1.2. the 
drug release need to controlled in pH 1.2 
because ondansetron solubility was found  
it is highly soluble in pH 1.2, whereas 
another object drug release need to 
enhance in pH 6.8 phosphate due to pH 
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dependent solubility [19-21].  Shows a 
lower percent of drug release at pH 6.8 as 
compared to pH 1.2, high percentage of 
drug release in pH in pH 1.2 it was found  
pH dependent drug release of ondansetron 
with HPMC. Incase witth Kollidon SR 
polymer drug release was found drastic 
change was  found, when concentration of 
kollidon sr was increased drug release was 
enhencced in both  pH  drug release was 
not controlled shown in (Fig.no 6).
 
 
Figure 6: Dissolution Profile of formulation with HPMC both pH 1.2 and 6.8 Phosphates 
Buffer. 
Optimization of Ondansetron HCl pH 
independent drug Release from the 
Prepared matrix Tablets: 
A summary of various dissolution 
parameters calculated for the entire batch, 
a significant fraction of the drug remained 
unreleased amount from the tablets 
without Kollidon® SR. Though the 
highest percentage of drug release among 
batches containing combination of both 
Methocel K100 with Kollidon® SR 
approximately 22.24% in pH 1.2 the drug 
release was controlled   and 96% of drug 
release at the end of 24h in both pH 
mediums respectively, it was clear that 
drug release was enhenced In pH 6.8 by 
influencing kollidon sr, the comparative 
analysis that combination of Methocel 
k100M with Kollidon SR improved drug 
release significantly. As the 
concentration of Kollidon SR increased, 
rate of drug release enhenced in pH 6.8 
phosphate buffer. The main reason for 
this kollidon SR is having 20%   
polyvinyl pyrolidine it controlled 
saturation of drug and enhancing drug 
release, and Methocel k100M is 
controlling the drug release with their 
high viscosity nature. The combination 
of Methocel and Kollidon® SR (F5)was 
found pH independent drug release for 
extended  up to 24h. The similarity of 
drug releas drug release in both pH was 
shown in (Fig.8). 
 
 
Figure 7: Effect of pH on in vitro drug release profile of optimised Ondansetron pH 
independent control release tablet (F-5). 
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Optimization data analysis 
In order to find out optimized batch based 
on set criteria, 3
2
 full factorial designs 
were applied. From the data obtained for 
factorial batches, ANOVA was performed 
to evaluate responses by a statistical model 
incorporating polynomial and interactive 
terms: The combination of Methocel and 
Kollidon® SR Matrix system optimized 
formulation had similar dissolution profile 
in both 6.8 phosphate buffer and pH 1.2 to 
each other (f2 >50) showing pH 
independent drug release of ondansetron 
HCl from the tablet . 
Y = β0 + β1X1 + β2X2 + β3X3+ 
β12X1X2+ β23X2X3+ β31X3X1+ 
β123X1X2 X3 
 
The in vitro release data plotted different 
drug release graphs from all the 
formulations could be best expressed by 
Higuchi’s Equation, as the coefficient 
values showed high linearity with R2 
values between 0.958 to 0.991. It 
indicating that diffusion mechanism 
involved in the release of the drug from 
the tablets it proves the diffusion 
mechanism; the data were fit in to 
Korsmeyer Peppas Eqn. From the slope ‘n’ 
values ranging from 0.527 to 0.715, the 
diffusion mechanism involved in 
formulations was considered to be non-
Fickian. [22-23]. When compared to all 
the nine formulations, formulation F-5 
Methocel k100M:Kollidon SR in 1:1 ratio 
released 96.21% of Ondansetro HCl in 24h 
was selected as the optimized formulations.  
the optimized formulation followed zero 
order release kinetics with diffusive 
mechanism by non-Fickian (Table.6).
 
Table 6: Drug Release kinetics of Formulated Matrix Tablets. 
Formulation code 
Zero order plots 
Regression 
coeffient(R) st 
order plots 
First order plots 
Regression 
coeffient(R)st 
order plots 
Highuchi’plots 
Regression 
coeffient(R) 
Korsmeyer’plot 
Regression 
coeffient(R) 
Slope 
(n) 
 
F1 0.976 0.864 0.991 0.992 0.555 
F2 0.989 0.961 0.986 0.997 0.549 
F3 0.997 0.919 0.959 0.987 0.638 
F4 0.986 0.854 0.989 0.978 0.528 
F5 0.975 0.867 0.963 0.979 0.627 
F6 0.984 0.929 0.979 0.976 0.704 
F7 0.980 0.936 0.975 0.963 0.715 
F8 0.996 0.879 0.987 0.971 0.542 
F9 0.988 0.936 0.995 0.991 0.564 
 
CONCLUSION 
In present investigation effect of Kollidon 
SR and their combination on drug release 
kinetics was studied using 3
2 
 factorial 
design .the investigations concluded that 
combination of kollidon sr and Methocel 
k100 containing weakly basic Ondansetron 
HCl improved release kinetics of the drug . 
Thus to avoid precipitation out of pH 
dependent weakly basic drugs these 
technique is useful for pH independent 
controlled released system. It was 
concluded that Kollidon® SR is a 
potentially useful polymer for the 
production of pH-independent controlled 
release matrix tablets. 
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